Teon Therapeutics is a San Francisco-based clinical-stage biopharmaceutical company led by founder and CEO Lina Yao, MD, Ph.D. The company develops small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways in the tumor microenvironment. Its lead program is an A2BR-selective antagonist, TT-702, which the company planned to advance into Phase 1b trials in 2021. Teon intends to use financing to advance TT-702 into the clinic and to build its pipeline. The company's leadership includes experts in adenosine and GPCR therapeutics who were primary inventors of Lexiscan, the only FDA-approved selective adenosine therapeutic.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2021